AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Summit Therapeutics Inc. Director's Dealing 2021

Dec 17, 2021

30436_dirs_2021-12-17_4a863b70-3b1b-4df6-a03e-4f36d63c2565.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2021-12-15

Reporting Person: Zanganeh Maky (Director, Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-15	Stock Option (right to buy)	$4.75	A	15000	Acquired	2031-12-15	Common Stock (15000.0)	Direct

Footnotes

F1: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date).

F2: (2) Not applicable.